Effects of Sorafenib, a Tyrosin Kinase Inhibitor, on Adrenocortical Cancer.
Front Endocrinol (Lausanne)
; 12: 667798, 2021.
Article
in En
| MEDLINE
| ID: mdl-34108938
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Gene Expression Regulation, Neoplastic
/
Adrenal Cortex Neoplasms
/
Adrenocortical Carcinoma
/
Sorafenib
/
Antineoplastic Agents
Type of study:
Guideline
/
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Front Endocrinol (Lausanne)
Year:
2021
Document type:
Article
Affiliation country:
Italy
Country of publication:
Switzerland